Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

hVIVO analysts raise forecasts after prelims

Analysts following hVIVO PLC have made some modest upgrades to earnings forecasts in the wake of the contract research group’s better-than-expected prelims.

Number crunchers at Liberum have increased their 2023 EBITDA number by 4% to £9.4mln, while their counterparts at finnCap have tweaked up the number by £600,000 to £9mln, while forecast profit before tax forecast rises £300,000 to £5.6mln.

finnCap kept its price target unchanged at 35p, while Liberum has increased its valuation by 1.2p to 26.3p.

In afternoon trade, hVIVO stock was changing hands for 17p, valuing the business at £115mln.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK